ing, apneas, hypopneas, and respiratory-related arousals disappeared in both NREM and REM in the supine body position. APAP pressures were set at a minimum pressure of 3.0 cm H 2 O and a maximum pressure of 20 cm H 2 O. Patients were randomly assigned to either the CPAP or APAP group by whether the last digit of their hospital number was even or odd.
During the first visit with the study coordinator the protocol was again reviewed, the Epworth Sleepiness Scale 16 (ESS) was administered, machine care and cleaning procedures were reviewed, and mask fit was determined. Patients were placed on the Respironics Virtuoso Smart-CPAP System, set for their randomized initial mode, CPAP or APAP. Two weeks following the initial visit, the patient was telephoned to inquire about his or her experience with the machine. If the patient was having trouble with the machine, a follow-up session was arranged with the study coordinator. Otherwise, monthly visits were arranged to assess patient sleepiness with ESS, record CPAP or APAP use time and pattern, and to address any equipment problems. At twelve weeks, the patient was switched to the alternative form of therapy, CPAP or APAP. Patients were followed as during the first ½ of study.
Data Analysis. Data were downloaded from the Virtuoso machine to a PC using the Encore Data Management Software ® (Respironics Inc.). Compiled data included clock time of machine use to supply the amount of time the machine was used and the pattern of use. The noninvasive pressure support devices contained a machine use clock. Machine-on time when there was pressure within the system was recorded. At monthly visits, machine-use pattern was transferred to storage on a PC. Chi-square was used for non-continuous data analysis. Paired t test was used compare CPAP and APAP continuous data. Significance level was p< 0.05. Table 1 displays the demographic data of the patient population. Sixty patients started the protocol, including seven with UARS. Twenty-one patients did not finish the 24-week protocol, including three with UARS. Two of these were discontinued because of medical complications, unrelated to the OSA. Thirtynine patients completed the protocol, including four with UAR syndrome. Of those who completed the study, pressure and machine usage data could not be downloaded for six subjects, but ESS data are available on these subjects. There were no differences in age, BMI, and gender distribution between the 39 patients who completed the study vs. the 19 that did not complete the study on their own accord. The mean age of the whole group was 46±1 (SEM) years, and the BMI was 42±2 kg/m2. The group was composed of 18 females and 21 males. A higher proportion of patients, 11 of 25 patients who began the study with CPAP dropped out compared to eight of 25 who began with APAP (p < 0.01). n/a n/a Post-APAP 8 ± 1 10 ± 2 9 ± 1 n/a n/a CPAP and APAP Pressures. The CPAP titration pressure ranged from 8 to 16 cm H 2 O with a mean value of 10.6±0.4 cm H 2 O. The APAP pressure recorded throughout the sleep period ranged from 3 to 13 cm H 2 O with a mean pressure of 6.4 ± 0.4 cm H 2 O (p<0.0001 from CPAP).
RESULTS

Patient Characteristics.
Daytime Sleepiness. The Epworth Sleepiness scale improved on both the CPAP and the APAP. The sleepiness score decreased from 15±1 to 8±1 on CPAP and to 9±1 on APAP after three months of therapy. Individual monthly scores from the first two months of the therapeutic period with each mode of therapy were not different than the thirdmonth scores. Sleepiness scores on therapy were less than baseline (p<0.0001), but not different from each other.
Device Use Pattern. Most use patterns were similar with the two devices. For instance, CPAP was used on 82 ± 4% of the study days (nights) and APAP was used on 84±4% of these days (NS). CPAP and APAP were used four hours or more on 66±5% and 73±5% of the nights, respectively (p=0.07). During the nights of machine use the number of hours of machine use was different, 5.5±0.3 hrs. for CPAP and 6.0±0.3 hrs. for APAP (p<0.04), although the total cumulative hours of machine use was similar, 428±37 hrs. for CPAP and 492±40 hrs. for APAP (NS). There was no difference in either CPAP or APAP compliance over the three months of the study.
Upper Airway Resistance Syndrome (UARS). Four patients with UARS completed the study. Three subjects were female and their BMI was less than the study group as a whole, 37±8 vs. 41±2 kg/m 2 . In this small group the Epworth Sleepiness Scale improved with both CPAP and APAP, decreasing from the baseline value of 18 ± 0.3 to 6±2 with CPAP and 5±2 with APAP at the end of month three of therapy (P<0.05 from baseline but NS between modes). Results were similar using the average of the three months of therapy for each mode of pressure support, 8±1 cm H 2 O for CPAP and 7±3 cm H 2 O for APAP ( P < 0.04 from initial value and not different from each other). UARS patients used APAP for a greater accumulative number of hours, 398±122 versus 298±113 for CPAP (p<0.03). On 57±14% of nights, they used APAP greater than four hours per night compared to 43±11% of nights for CPAP (p<0.04).
DISCUSSION
Summary. This study demonstrated that the average pressure recorded overnight was lower with APAP than with CPAP, and that APAP was used for a longer period of time per night than CPAP in both OSA and UARS patients. The same degree of improvement in daytime sleepiness symptoms was documented with each mode of pressure support for OSA and UARS. Interestingly, 19 of 60, 32% of the population, that agreed to use the pressure support machine for treatment of OSA or UARS did not follow through with this treatment. Subjects who began treatment with CPAP were more likely to drop out than if they began treatment with APAP. Those who finished the study were quite compliant, in that they utilized their equipment on over 80% of nights and longer than four hours per night, on over 65% of the nights. These results illustrate that OSA and UARS patients given APAP may be more likely to stay on treatment and that APAP may be better tolerated than CPAP by both patients with OSA and UARS. Obviously, we cannot be as confident in this conclusion about UARS patients as about OSA patients since the number of UARS patients was small. In spite of the increased APAP use, the clinical outcome, as assessed by one index of excessive daytime sleepiness was the same with CPAP and APAP modes of therapy.
Comparison of these findings with the work of others. Other studies have shown that APAP is effective in resolving sleep-disordered breathing. Uncontrolled or short-term studies demonstrated that APAP controls OSA in most, but not all patients. APAP was demonstrated to be effective in fifteen OSA patients already on CPAP, who were switched to APAP for two months in an uncontrolled study. 8 In these patients, the ESS scores were similar on the two devices. In a randomized parallel design, Ficker et al. 9 began eight newly diagnosed OSA patients on APAP and eight on CPAP for one night. On therapy, polysomnograms showed equivalent improvement in OSA, arousals, and sleep architecture with APAP and CPAP. Vigilance and sleepiness improved similarly. Different from our findings, the average APAP pressure was significantly higher than the CPAP pressure in this study. In a study intended to use APAP to predict the optimal CPAP titration pressure, Lloberes et al found no added sleep disruption with the changing APAP pressures during sleep. 10 In a single night randomized, cross-over comparison of APAP with CPAP in 12 OSA patients, Scharf et al. 11 found equivalent control of apneas, improved sleep at a lower mean pressure with APAP relative to CPAP. In 20 OSA patients with a similar design, Sharma et al 12 found equivalent improvement in OSA, arousals, sleep architecture and oxygenation. However, the APAP device did not maintain baseline pressure nor increase pressure appropriately in seven of the 20 patients. Lofaso et al 17 found that if the APAP was dependent on nasal mask pressure vibration alone that it did not effectively resolve OSA in REM sleep in 12 of 15 patients.
Little controlled data are available comparing the effectiveness of and compliance with CPAP and APAP over time. In a parallel group design with eight subjects in each group studied for three weeks, Meurice et al. 18 found that a self-titrating APAP machine was effective in resolving OSA and its sequelae equivalent to that of CPAP, but at a lower average pressure than needed with CPAP. Patients were able to wear the APAP device for a greater number of hours than CPAP. These results are similar to those of the current study, in spite of the differences in design of the two studies. In a longer parallel study of three to six months, Konermann et al. 19 found that OSA was resolved similarly with APAP and CPAP, and that sleep quality was restored similarly with each device. These investigators did not evaluate changes in apnea sequelae.
To more ideally control for subject characteristics and disease severity, we chose a randomized, cross-over study design. We blinded the application of the mode of therapy and used an extended therapeutic period of three months. We assessed changes in excessive daytime sleepiness, a common symptom associated with OSA. We also studied UARS patients, although the number of these patients available for study was limited. In this long-term trial, we found that neither CPAP nor APAP compliance changed over the three months of the study.
With use of a randomized, cross-over design, it would be logical to conclude that the increased wear time found with APAP indicated improved tolerance of this therapeutic modality over CPAP. This improved tolerance and longer wear time would be expected to be associated with a better clinical outcome. However, we did not find this. We found an equivalent improvement in daytime sleepiness, as measured by the ESS, in spite of the lower pressure and longer wear time found with APAP. Possible explanations of this inconsistency are: 1) The difference in wear time was not enough to result in a different clinical outcome; 2) The improvement in the ESS with CPAP was near maximum obtainable with pressure support treatment; and therefore, it would be nearly impossible to show further improvement with APAP, and 3) Other outcome variables might have shown preferential improvement if measured.
Our results indicate that for some OSA and UARS patients, possibly patients with poor tolerance of and inadequate compliance with CPAP, APAP would be an alternative choice. If these patients were able to utilize the APAP device, their therapeutic response likely would be similar to that obtained with CPAP.
